Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia

Abstract Proteasome inhibitors (PIs) bortezomib, carfilzomib and ixazomib are approved for the treatment of multiple myeloma and mantle cell lymphoma and have clinical activity in acute lymphoblastic leukemia (ALL). The predominant form of proteasome in these hematologic malignancies is the lymphoid...

Full description

Saved in:
Bibliographic Details
Main Authors: Tyler W. Jenkins, Jacquelyn Elise Fitzgerald, Jieun Park, Addison M. Wilson, Kristy L. Berry, Keith S. Wong, Walid A. Houry, Irene Lee, Andrey V. Maksimenko, Peter R. Panizzi, Yulia Y. Maxuitenko, Matthew Shane Loop, Amit K. Mitra, Alexei F. Kisselev
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-01657-0
Tags: Add Tag
No Tags, Be the first to tag this record!